Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients

Journal of Clinical Oncology

Volumn 23, Issue 18, 2005, Pages 4089-4099

  Badros, Ashraf Z ^a   Goloubeva, Olga ^a   Rapoport, Aaron P ^a   Ratterree, Bashi ^a   Gahres, Natalie ^a   Meisenberg, Barry ^a   Takebe, Naoko ^a   Heyman, Meyer ^a   Zwiebel, James ^a   Streicher, Howard ^a   Gocke, Christopher D ^a   Tomic, Dragana ^a   Flaws, Jodi A ^a   Zhang, Bin ^a   Fenton, Robert G ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BCL 2 ANTISENSE OLIGONUCLEOTIDE; BISPHOSPHONIC ACID DERIVATIVE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DAPSONE; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; FAMCICLOVIR; FLUCONAZOLE; GABAPENTIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN M; LAXATIVE; LEVOFLOXACIN; MESSENGER RNA; OBLIMERSEN; PARACETAMOL; PLATINUM; PROTEIN BCL 2; THALIDOMIDE; UNCLASSIFIED DRUG; WARFARIN; ANTINEOPLASTIC AGENT; NUCLEOTIDE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CATHETER THROMBOSIS; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DEPRESSION; DROWSINESS; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; EDEMA; ELECTROLYTE DISTURBANCE; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; FEVER; FLUSHING; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERMAGNESEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOTENSION; HYPOXEMIA; IMMUNE RESPONSE; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LOW DRUG DOSE; LUNG HYPOXEMIA; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE CRAMP; MYELOMA CELL; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN ISOLATION; PSYCHOPATHY; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; THROMBOSIS; THYROTROPIN BLOOD LEVEL; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; VOMITING; WEAKNESS; WESTERN BLOTTING; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; RECURRENT DISEASE; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; DEXAMETHASONE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OLIGONUCLEOTIDES, ANTISENSE; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; THALIDOMIDE; THIONUCLEOTIDES; TREATMENT OUTCOME;

EID: 23044452536     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.14.381     Document Type: Article

References (46)

1. Sirohi B, Powles R: Multiple myeloma. Lancet 363:875-887, 2004
2. Dimopoulos MA, Anagnostopoulos A, Weber D: Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 21:4444-4454, 2003
3. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
4. Cory S, Huang DC, Adams JM: The Bcl-2 family. Roles in cell survival and oncogenesis. Oncogene 22:8590-8607, 2003
5. Harada N, Hata H, Yoshida M, et al: Expression of Bcl-2 family of proteins in fresh myeloma cells. Leukemia 12:1817-1820, 1998
6. Hamilton MS, Barker HF, Ball J, et al: Normal and neoplastic human plasma cells express bcl-2 antigen. Leukemia 5:768-771, 1991
7. Menendez P, Vargas A, Bueno C, et al: Quantitative analysis of bcl-2 expression in normal and leukemia human B-cell differentiation. Leukemia 18:491-498, 2004
8. Tu Y, Xu FH, Liu J, et al: Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood 88:1805-1812, 1996
9. Gazitt Y, Fey V, Thomas C, et al: Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells. Int J Oncol 13:397-405, 1998
10. Gazitt Y, Rothenberg ML, Hilsenbeck SG, et al: Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Int J Oncol 13:839-848, 1998
11. Miguel-Garcia A, Orero T, Matutes E, et al: Bcl-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: A comparative study. Haematologica 83:298-304, 1998
12. Ong F, van Nieuwkoop JA, de Groot-Swings GM, et al: Bcl-2 protein expression is not related to short survival in multiple myeloma. Leukemia 9:1282-1284, 1995
13. Klasa RJ, Gillum AM, Klem RE, et al: Oblimersen Bcl-2 antisense: Facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 12:193-213, 2002
14. Van de Donk, Kamphuis M, Van Dijk M, et al: Evaluation of bcl-2 antisense oligonucleotide drugs in multiple myeloma. Blood 96:757a, 2000 (abstr)
15. Liu Q, Gazitt Y: Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells. Blood 101:4105-4114, 2003
16. Zhang B, Gojo I, Fenton RG: Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 99:1885-1893, 2002
17. van de Donk NW, Kamphuis MM, van Dijk M, et al: Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia 17:211-219, 2003
18. Blade J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT-European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123, 1998
19. Lee CK, Barlogie B, Munshi N, et al: DTPACE: An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 21:2732-2739, 2003
20. Morris MJ, Tong WP, Cordon-Cardo C, et al: Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 8:679-683, 2002
21. Waters JS, Webb A, Cunningham D, et al: Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18:1812-1823, 2000
22. Marshall J, Chen H, Yang D, et al: A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol 15:1274-1283, 2004
23. Rudin CM, Kozloff M, Hoffman PC, et al: Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 22:1110-1117, 2004
24. Tolcher AW, Kuhn J, Schwartz G, et al: A phase I pharmacokinetic and biological correlative study of oblimersen sodium (Genasense, G3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 10:5048-5057, 2004
25. Raynaud FI, Orr RM, Goddard PM, et al: Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther 281:420-427, 1997
26. Marcucci G, Byrd JC, Dai G, et al: Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 101:425-432, 2003
27. Chi KN, Gleave ME, Klasa R, et al: A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 7:3920-3927, 2001
28. Henry SP, Beattie G, Yeh G, et al: Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int Immunopharmacol 2:1657-1666, 2002
29. Levin AA: A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1489:69-84, 1999
30. Chanan-Khan A, Niesvisky R, Hohl R, et al: Randomized multicenter phase 3 trial of high-dose dexamethasone (dex) with or without oblimersen sodium (G3139; Bcl-2 antisense; Genasense) for patients with advanced multiple myeloma (MM). Blood 104:1477a, 2004 (abstr)
31. Graham LD, Mitchell SM, Underwood PA: Inhibition of platelet heparitinase by phosphorothioate DNA oligonucleotides. Biochem Mol Biol Int 37:239-246, 1995
32. Drygin D, Barone S, Bennett CF: Sequence-dependent cytotoxicity of second-generation oligonucleotides. Nucleic Acids Res 32:6585-6594, 2004
33. Zangari M, Barlogie B, Anaissie E, et al: Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: Effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126:715-721, 2004
34. Apfel SC, Zochodne DW: Thalidomide neuropathy: Too much or too long? Neurology 62:2158-2159, 2004
35. Dimopoulos MA, Zervas K, Kouvatseas G, et al: Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12:991-995, 2001
36. Anagnostopoulos A, Weber D, Rankin K, et al: Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121:768-771, 2003
37. Tosi P, Zamagni E, Cellini C, et al: Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 73:98-103, 2004
38. Palumbo A, Bertola A, Falco P, et al: Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 5:318-324, 2004
39. van de Donk NW, de Weerdt O, Veth G, et al: G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma. Leukemia 18:1078-1084, 2004
40. Krieg AM, Yi AK, Matson S, et al: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-549, 1995
41. Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709-760, 2002
42. Jahrsdorfer B, Jox R, Muhlenhoff L, et al: Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J Leukoc Biol 72:83-92, 2002
43. Verthelyi D, Klinman DM: Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin Immunol 109:64-71, 2003
44. Wacheck V, Krepler C, Strommer S, et al: Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice. Antisense Nucleic Acid Drug Dev 12:359-367, 2002
45. Krieg AM, Davis HL: Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther 3:15-24, 2001
46. Klinman DM: Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 4:249-258, 2004